Cited 16 times in
Efficacy of oxaliplatin-based chemotherapy in curatively resected colorectal cancer with liver metastasis
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김남규 | - |
dc.contributor.author | 김진수 | - |
dc.contributor.author | 김혜련 | - |
dc.contributor.author | 노재경 | - |
dc.contributor.author | 라선영 | - |
dc.contributor.author | 민병소 | - |
dc.contributor.author | 신상준 | - |
dc.contributor.author | 안중배 | - |
dc.date.accessioned | 2014-12-20T17:40:29Z | - |
dc.date.available | 2014-12-20T17:40:29Z | - |
dc.date.issued | 2011 | - |
dc.identifier.issn | 0030-2414 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/95047 | - |
dc.description.abstract | OBJECTIVES: Although surgical resection alone has been validated as a standard treatment for patients with liver metastases from colorectal cancer, a high rate of recurrence is still an issue to be overcome. We aimed to assess the efficacy of adjuvant chemotherapy using an oxaliplatin-based regimen in patients who underwent hepatic and primary colorectal cancer resection. METHODS: Sixty patients who received oxaliplatin-based postoperative chemotherapy combined with curative resection of primary colorectal cancer and synchronous liver metastases between January 2000 and February 2008 were retrospectively reviewed. The Kaplan-Meier method was used to estimate survival, and prognostic factors were evaluated with the log-rank test. RESULTS: Median overall survival (OS) was 62.8 months [95% confidence interval (CI) 44.1-81.3], and median relapse-free survival (RFS) was 32.8 months (95% CI 5.8-59.6). The 1-, 3- and 5-year survival rates were 95.0, 68.8 and 55.5%, respectively. The relapse-free interval and modality of liver resection were independently associated with OS. CONCLUSIONS: Oxaliplatin-based adjuvant chemotherapy after radical resection resulted in increased OS and RFS with acceptable tolerability compared to surgery alone. However, it is not yet clear whether postoperative oxaliplatin-based chemotherapy improves outcome compared to patients treated with 5-fluorouracil plus leucovorin. | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 175~183 | - |
dc.relation.isPartOf | ONCOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols/adverse effects | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols/therapeutic use* | - |
dc.subject.MESH | Chemotherapy, Adjuvant | - |
dc.subject.MESH | Colorectal Neoplasms/drug therapy* | - |
dc.subject.MESH | Colorectal Neoplasms/pathology | - |
dc.subject.MESH | Colorectal Neoplasms/secondary | - |
dc.subject.MESH | Colorectal Neoplasms/surgery* | - |
dc.subject.MESH | Disease-Free Survival | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Fluorouracil/administration & dosage | - |
dc.subject.MESH | Follow-Up Studies | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Kaplan-Meier Estimate | - |
dc.subject.MESH | Leucovorin/administration & dosage | - |
dc.subject.MESH | Liver Neoplasms/drug therapy* | - |
dc.subject.MESH | Liver Neoplasms/pathology | - |
dc.subject.MESH | Liver Neoplasms/surgery* | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Neoplasm Metastasis | - |
dc.subject.MESH | Organoplatinum Compounds/administration & dosage | - |
dc.subject.MESH | Organoplatinum Compounds/adverse effects | - |
dc.subject.MESH | Prognosis | - |
dc.subject.MESH | Retrospective Studies | - |
dc.subject.MESH | Survival Rate | - |
dc.title | Efficacy of oxaliplatin-based chemotherapy in curatively resected colorectal cancer with liver metastasis | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학) | - |
dc.contributor.googleauthor | Kim H.R. | - |
dc.contributor.googleauthor | Min B.S. | - |
dc.contributor.googleauthor | Kim J.S. | - |
dc.contributor.googleauthor | Shin S.J. | - |
dc.contributor.googleauthor | Ahn J.B. | - |
dc.contributor.googleauthor | Rho J.K. | - |
dc.contributor.googleauthor | Kim N.K. | - |
dc.contributor.googleauthor | Rha S.Y | - |
dc.identifier.doi | 10.1159/000333440 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A00353 | - |
dc.contributor.localId | A01166 | - |
dc.contributor.localId | A01290 | - |
dc.contributor.localId | A01402 | - |
dc.contributor.localId | A02105 | - |
dc.contributor.localId | A02262 | - |
dc.contributor.localId | A01021 | - |
dc.contributor.localId | A01316 | - |
dc.relation.journalcode | J02416 | - |
dc.identifier.eissn | 1423-0232 | - |
dc.identifier.pmid | 22057187 | - |
dc.identifier.url | http://www.karger.com/Article/FullText/333440 | - |
dc.subject.keyword | Adjuvant chemotherapy | - |
dc.subject.keyword | Colorectal neoplasms | - |
dc.subject.keyword | Liver metastasis | - |
dc.subject.keyword | Oxaliplatin | - |
dc.contributor.alternativeName | Kim, Nam Kyu | - |
dc.contributor.alternativeName | Kim, Jin Soo | - |
dc.contributor.alternativeName | Kim, Hye Ryun | - |
dc.contributor.alternativeName | Roh, Jae Kyung | - |
dc.contributor.alternativeName | Rha, Sun Young | - |
dc.contributor.alternativeName | Min, Byung Soh | - |
dc.contributor.alternativeName | Shin, Sang Joon | - |
dc.contributor.alternativeName | Ahn, Joong Bae | - |
dc.contributor.affiliatedAuthor | Kim, Nam Kyu | - |
dc.contributor.affiliatedAuthor | Kim, Hye Ryun | - |
dc.contributor.affiliatedAuthor | Roh, Jae Kyung | - |
dc.contributor.affiliatedAuthor | Min, Byung Soh | - |
dc.contributor.affiliatedAuthor | Shin, Sang Joon | - |
dc.contributor.affiliatedAuthor | Ahn, Joong Bae | - |
dc.contributor.affiliatedAuthor | Kim, Jin Soo | - |
dc.contributor.affiliatedAuthor | Rha, Sun Young | - |
dc.rights.accessRights | not free | - |
dc.citation.volume | 81 | - |
dc.citation.number | 3-4 | - |
dc.citation.startPage | 175 | - |
dc.citation.endPage | 183 | - |
dc.identifier.bibliographicCitation | ONCOLOGY, Vol.81(3-4) : 175-183, 2011 | - |
dc.identifier.rimsid | 27006 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.